Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.
Sham Mailankody, MBBS, discussed the challenge of determining an optimal sequence of treatments in patients with relapsed/refractory multiple myeloma, and how head-to-head studies can help.
Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to implement shared decision-making when discussing treatment options with your patients.
The National Comprehensive Cancer Network recently issued new guidelines on best practices in evaluating patients for hematopoietic cell transplantation, as well as how to manage complications associated with the procedure.
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone.
How much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.
CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease.